APA (7th ed.) Citation

P, A., S, K., C, T., M, P., S, U., AC, B., . . . R, Z. (2023). Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. British journal of haematology, 203(2), 264. https://doi.org/10.1111/bjh.19007

Chicago Style (17th ed.) Citation

P, Apostolova, et al. "Phase II Trial of Hypomethylating Agent Combined with Nivolumab for Acute Myeloid Leukaemia Relapse After Allogeneic Haematopoietic Cell Transplantation-Immune Signature Correlates with Response." British Journal of Haematology 203, no. 2 (2023): 264. https://doi.org/10.1111/bjh.19007.

MLA (9th ed.) Citation

P, Apostolova, et al. "Phase II Trial of Hypomethylating Agent Combined with Nivolumab for Acute Myeloid Leukaemia Relapse After Allogeneic Haematopoietic Cell Transplantation-Immune Signature Correlates with Response." British Journal of Haematology, vol. 203, no. 2, 2023, p. 264, https://doi.org/10.1111/bjh.19007.